2CL.F BridgeBio Pharma, Inc.
- Market cap
- EUR 13.7B
- P/E
- -
- P/B
- 127.53x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 2CL.F undervalued?
Graham numberThe Graham number of BridgeBio Pharma, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BridgeBio Pharma, Inc. fundamental analysis
No fundamental analysis for BridgeBio Pharma, Inc. yet.
BridgeBio Pharma, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NU…
Full company profileBridgeBio Pharma, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BridgeBio Pharma, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 77.6M | 9.30M | 222M | 502M | 1.06B |
| Gross Profit | 74.2M | 6.86M | 218M | 481M | 995M |
| Operating Income | -468M | -599M | -577M | -502M | -300M |
| EBITDA | -397M | -565M | -437M | -549M | -287M |
| Net Income | -481M | -643M | -536M | -725M | -497M |
| EPS | -3.19 | -3.67 | -2.82 | -3.72 | -2.54 |
| Balance Sheet | |||||
| Total Assets | 623M | 546M | 919M | 936M | 2.16B |
| Total Liabilities | 1.87B | 1.89B | 2.38B | 3.01B | 3.82B |
| Shareholders' Equity | -1.25B | -1.35B | -1.47B | -2.09B | -1.66B |
| Cash & Short-term Investments | 377M | 376M | 681M | 570M | 1.53B |
| Cash Flow | |||||
| Operating Cash Flow | -419M | -528M | -521M | -446M | -417M |
| Capital Expenditure | 6.32M | 1.31M | 8.91M | 9.59M | 1.07M |
| Free Cash Flow | -426M | -529M | -530M | -456M | -418M |
| Ratios | |||||
| ROA | -77.2% | -117.7% | -58.3% | -77.4% | -23.0% |
| Net Profit Margin | -619.7% | -6,913.9% | -241.4% | -144.4% | -47.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BridgeBio Pharma, Inc. dividends
BridgeBio Pharma, Inc. has not paid dividends in the last 4 fiscal years.
Who owns BridgeBio Pharma, Inc.
- Insiders 3.93%
- Institutions 96.08%
- Public & others 0.00%
- Shares outstanding 195M
- Free float 167M
BridgeBio Pharma, Inc. company profile
- Company name
- BridgeBio Pharma, Inc.
- Ticker
- 2CL.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,081
- Fiscal year end
- December
- Address
- 3160 Porter Drive, Palo Alto, CA, United States, 94304
- Phone
- 650 391 9740
- Website
- bridgebio.com
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
BridgeBio Pharma, Inc. management
10- Dr. Neil Kumar Ph.D.Co-Founder, CEO & Director · born 1979
- Dr. Thomas Trimarchi Ph.D.CFO & President · born 1985
- Dr. Charles J. Homcy M.D.Co-Founder, Chairman of Pharmaceuticals & Lead Director · born 1948
- Dr. Frank P. McCormick Ph.D.Co-Founder, Chairman of Oncology & Director · born 1950
- Ms. Maricel M. ApuliChief Accounting Officer · born 1977
- Dr. Uma Sinha Ph.D.Chief Scientific Officer · born 1958
- Dr. Richard H. Scheller Ph.D.Chairman of Research & Development · born 1953
- Mr. Eli M. Wallace Ph.D.Chief Scientific Officer of Oncology · born 1967
- Dr. Eric Michael David J.D., M.D., Ph.D.Chief Executive Officer of Gene Therapy · born 1972
- Mr. Matthew Outten CPC, MBAChief Commercial Officer · born 1974